We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Stock Moves -0.8%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Bristol-Myers Squibb (BMY - Free Report) closed at $48.40, marking a -0.8% move from the previous day. This change was narrower than the S&P 500's daily loss of 4.34%. Elsewhere, the Dow lost 4.55%, while the tech-heavy Nasdaq lost 3.79%.
Heading into today, shares of the biopharmaceutical company had lost 25.13% over the past month, lagging the Medical sector's loss of 22.08% and outpacing the S&P 500's loss of 28.78% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. In that report, analysts expect BMY to post earnings of $1.47 per share. This would mark year-over-year growth of 33.64%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.97 billion, up 68.33% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.13 per share and revenue of $41.78 billion. These results would represent year-over-year changes of +30.7% and +59.81%, respectively.
Any recent changes to analyst estimates for BMY should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.31% lower. BMY is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, BMY is holding a Forward P/E ratio of 7.95. For comparison, its industry has an average Forward P/E of 12.64, which means BMY is trading at a discount to the group.
We can also see that BMY currently has a PEG ratio of 0.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 1.66 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 80, putting it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Stock Moves -0.8%: What You Should Know
In the latest trading session, Bristol-Myers Squibb (BMY - Free Report) closed at $48.40, marking a -0.8% move from the previous day. This change was narrower than the S&P 500's daily loss of 4.34%. Elsewhere, the Dow lost 4.55%, while the tech-heavy Nasdaq lost 3.79%.
Heading into today, shares of the biopharmaceutical company had lost 25.13% over the past month, lagging the Medical sector's loss of 22.08% and outpacing the S&P 500's loss of 28.78% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. In that report, analysts expect BMY to post earnings of $1.47 per share. This would mark year-over-year growth of 33.64%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.97 billion, up 68.33% from the year-ago period.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.13 per share and revenue of $41.78 billion. These results would represent year-over-year changes of +30.7% and +59.81%, respectively.
Any recent changes to analyst estimates for BMY should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.31% lower. BMY is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, BMY is holding a Forward P/E ratio of 7.95. For comparison, its industry has an average Forward P/E of 12.64, which means BMY is trading at a discount to the group.
We can also see that BMY currently has a PEG ratio of 0.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. BMY's industry had an average PEG ratio of 1.66 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 80, putting it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.